tiprankstipranks
PolyPid Reports Growth in Mid-Year Assets
Company Announcements

PolyPid Reports Growth in Mid-Year Assets

PolyPid (PYPD) has released an update.

Don't Miss our Black Friday Offers:

PolyPid Ltd., a pharmaceutical company, has reported its interim condensed consolidated financial statements for the period ending June 30, 2024. The unaudited report highlights a total asset increase to $19,527 thousand from $15,372 thousand at the end of the previous year. Additionally, the company shows a shareholders’ equity of $1,601 thousand, recovering from a deficit position.

For further insights into PYPD stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskPolyPid Reports Q3 Results Amid SHIELD II Trial Progress
TipRanks Auto-Generated NewsdeskPolyPid Announces SHIELD II Trial Progress and Financials
TheFlyPolyPid reports Q3 EPS ($1.22), consensus ($1.00)
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App